A single dose of 10-80 mg was tested in healthy males for changes in vital signs, ECG or laboratory safety parameters, and researchers found no changes. The drug performed well when looking at absorption and distribution in the body and showed the potential for once daily oral administration. The drug was designed to work similarly to other anti-neuropathic drugs without the common adverse effects.
Related Articles on Pain Management:
Stanford, UCSF to Test Ultrasound for Relieving Cancer Pain
Fibronectin Injection After Spinal Cord Injury Can Relieve Pain
Use of Opioids for Abdominal Pain More Than Doubled in Past Decade
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
